<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213641</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885D2401</org_study_id>
    <nct_id>NCT01213641</nct_id>
  </id_info>
  <brief_title>Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients</brief_title>
  <acronym>B-Confident</acronym>
  <official_title>An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to collect additional information regarding
      long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical
      practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To monitor and further explore the overall safey of canakinumab focusing in serious infections</measure>
    <time_frame>At least 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term impact of Ilaris on disease progression (including systemic AA amyloidosis as evidenced by renal function, neurologic and ophthalmologic symptoms, and sensorineural deafness)</measure>
    <time_frame>At least 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth and development patterns of children aged 4 to 18 years of age exposed to Ilaris</measure>
    <time_frame>at least 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify previously unrecognized serious adverse drug reactions in the treated population</measure>
    <time_frame>at least 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage and patterns of dosing of Ilaris in routine clinical practice</measure>
    <time_frame>at least 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious infections</measure>
    <time_frame>at least 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of malignancies</measure>
    <time_frame>at least 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypersensitivity reactions</measure>
    <time_frame>at least 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">288</enrollment>
  <condition>Cryopyrin-associated Periodic Syndromes (CAPS)</condition>
  <condition>Familial Cold Autoinflam Syn (FCAS)</condition>
  <condition>Muckle-wells Syn (MWS)</condition>
  <condition>Neonatal Onset Multisystem Inflam Disease (NOMID)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with CAPS and treated with canakinumab. Patients treated with
        canakinumab for other autoinflammatory diseases may be included where allowed per local
        regulations.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving Ilaris (canakinumab) at the time of enrollment as part of medical
             care

        Exclusion Criteria:

          -  Local regulations in some locations may exclude patients who receive Ilaris for a
             non-approved indication

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Little Rock Allergy and Asthma Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arizona</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Center at Brookstone</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - St. Lukes Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Bregenz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>March 25, 2016</last_update_submitted>
  <last_update_submitted_qc>March 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cryopyrin-associated periodic syndromes(CAPS)</keyword>
  <keyword>CIAS1 protein</keyword>
  <keyword>NLRP3 protein</keyword>
  <keyword>human cryopyrin protein</keyword>
  <keyword>Familial Cold Autoinflammatory Syndrome(FCAS)</keyword>
  <keyword>Muckle-Wells Syndrome(MWS)</keyword>
  <keyword>Neonatal Onset Multisystem Inflammatory disease(NOMID)</keyword>
  <keyword>NALP3</keyword>
  <keyword>canakinumab</keyword>
  <keyword>Interleukin-1(IL-1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

